Cologne, October 22, 2025 — Ningaloo Biosystems has released a new white paper presenting advances in its proprietary optogenetic platform, designed to bring light-controlled gene expression to industrial bioproduction. The study demonstrates how tunable, reversible control over protein expression can now be applied directly in mammalian production cell lines, enabling robust and scalable manufacturing of complex biologics.
By delivering up to 500-fold induction of gene expression in HEK and CHO cells, the platform allows precise, dynamic modulation of production outcomes. This capability supports more flexible and efficient optimization of protein yields and quality, bridging the gap between research innovation and industrial application.
These results establish optogenetics as a practical, controllable approach for mammalian bioproduction, offering a foundation for more adaptive and high-performing manufacturing processes.
Download the whitepaper here: Optogenetics in Bioproduction — Now you can
About Ningaloo
Ningaloo Biosystems is pioneering advancements in biopharmaceutical production by engineering host cells for real-time process control through optogenetics. This approach enables cybergenetic bioprocessing to achieve unprecedented efficiency in manufacturing complex proteins and gene therapeutics, ultimately reducing costs and expanding access to cutting-edge treatments.